Moreover, the adjustment for other potential genetic risk factors for MS (especially, the HLA DRB1*15:01 and HLA A*:02), as well as the selection of genotyped variants based on the tagging SNP method, could have provided a comprehensive picture of the CD33 gene and its role in MS. Here, CD33 is linked to myeloid sarcoma.